Outcome of colorectal cancer patients treated with combination bevacizumab therapy

• Verfasst von: Betge, Johannes [VerfasserIn]
• Verfasst von: Belle, Sebastian [VerfasserIn]
• Verfasst von: Zhan, Tianzuo [VerfasserIn]
• Verfasst von: Härtel, Nicolai [VerfasserIn]
• Verfasst von: Kripp, Melanie [VerfasserIn]
• Verfasst von: Hofheinz, Ralf-Dieter [VerfasserIn]
• Verfasst von: Gaiser, Timo [VerfasserIn]
• Verfasst von: Ebert, Matthias [VerfasserIn]
• Verfasst von: Schulte, Nadine [VerfasserIn]
• Titel: Outcome of colorectal cancer patients treated with combination bevacizumab therapy
• Titelzusatz: a pooled retrospective analysis of three European cohorts from the angiopredict initiative
• Verf.angabe: Johannes Betge, Ana Barat, Verena Murphy, Thomas Hielscher, Nicole C. Van Grieken, Sebastian Belle, Tianzuo Zhan, Nicolai Härtel, Melanie Kripp, Orna Bacon, Martijn Cordes, Elaine W. Kay, Henk M. W. Verheul, Maarten Neerincx, Bryan Hennessy, Ralf D. Hofheinz, Timo Gaiser, Bauke Ylstra, Jochen H. M. Prehn, Diether Lambrechts, Annette T. Byrne, Matthias P. Ebert, Nadine Schulte
• E-Jahr: 2016
• Jahr: October 19, 2016
• Umfang: 9 S.
• Fussnoten: Gesehen am 09.01.2019
• Titel Quelle: Enthalten in: Digestion
• Ort Quelle: Basel : Karger, 1968
• Jahr Quelle: 2016
• Band/Heft Quelle: 94(2016), 3, Seite 129-137
• ISSN Quelle: 1421-9867
• DOI: doi:10.1159/000449412
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1586070037

Abstract

Background/Aims: This study is aimed at analyzing the survival rates and prognostic factors of stage IV colorectal cancer patients from 3 European cohorts undergoing combination chemotherapy with bevacizumab. Methods: Progression free-survival (PFS) and overall survival (OS) were analyzed in 172 patients using the Kaplan-Meier method and uni- and multivariable Cox proportional hazards regression models. Results: The median PFS was 9.7 and the median OS 27.4 months. Patients treated at centers in Germany (n = 97), Ireland (n = 32), and The Netherlands (n = 43) showed a median PFS of 9.9, 9.2, and 9.7 months, OS of 34.0, 20.5, and 25.1 months, respectively. Patients >65 years had a significantly shorter PFS (9.5 vs. 9.8 months) but not OS (27.4 vs. 27.5 months) than younger patients. High tumor grade (G3/4) was associated with a shorter PFS, T4 classification with both shorter PFS and OS. Fluoropyrimidine (FP) chemotherapy backbones (doublets and single) had comparable outcomes, while patients not receiving FP backbones had a shorter PFS. In multivariable analysis, age and non-FP backbone were associated with inferior PFS, T4 classification and therapy line >2nd were significantly associated with poor PFS and OS. Conclusion: The observed survival rates confirm previous studies and demonstrate reproducible benefits of combination bevacizumab regimens. Classification T4, non-FP chemotherapy backbone, and age >65 were associated with inferior outcome.